Enzystal-P, 20 pcs.

Enzystal-P is an enzyme remedy.

It contains pancreatic enzymes – amylase, lipase and proteases that facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine.

In diseases of the pancreas, it compensates the insufficiency of its external secretory function and improves the digestive process.

Indications

Active ingredient

Composition

1 enteric-coated tablet contains:

the active ingredient:

Pancreatin 116.17 mg

How to take, the dosage

The dose (in terms of lipase) depends on age and degree of pancreatic insufficiency. Average dose for adults is 150,000 IU/day. In case of complete insufficiency of external pancreatic secretory function – 400 000 IU/day, which corresponds to daily lipase requirement of an adult person.

The maximum daily dose is 15,000 IU/kg.

In children under 1.5 years of age, 50,000 IU/day; over 1.5 years, 100,000 IU/day.

The duration of treatment may vary from a few days (when digestion is disturbed due to errors in diet) to several months or even years (if permanent replacement therapy is necessary).

Interaction

Concomitant use with antacids containing calcium carbonate and/or magnesium hydroxide may decrease the effectiveness of pancreatin.

Concomitant use may theoretically reduce the clinical efficacy of acarbose.

Concomitant use of iron preparations may decrease the absorption of iron.

Special Instructions

The use in the acute phase of chronic pancreatitis is not recommended.

In cystic fibrosis, the dose should be adequate to the amount of enzymes required for fat absorption, taking into account the quality and quantity of food consumed.

Pancreatin doses greater than 10 000 units/kg/day (in terms of lipase) are not recommended in cystic fibrosis because of the increased risk of strictures (fibrous colonopathy) in the ileocecal and ascending colon.

The high lipase activity of pancreatin increases the likelihood of constipation in children. Increasing the dose of pancreatin in this category of patients should be done gradually.

Disorders of the digestive system may occur in patients with hypersensitivity to pancreatin, or in patients with a history of meconium ileus or bowel resection.

Contraindications

Acute pancreatitis, hypersensitivity to pancreatin.

Side effects

When used in average therapeutic doses, side effects are observed in less than 1%.

Digestive system disorders: in some cases – diarrhea, constipation, feeling of discomfort in the stomach, nausea. The cause-and-effect relation of development of these reactions with the action of pancreatin has not been determined, because the above phenomena are related to the symptoms of extrasecretory pancreatic failure.

Allergic reactions: in some cases – skin manifestations.

Metabolism disorders: in prolonged use in high doses hyperuricosuria is possible; in excessive doses – increase in plasma uric acid level.

Others: perianal irritation may occur with pancreatin in high doses in children.

Pregnancy use

The safety of pancreatin use in pregnancy has not been adequately studied. Use is possible in cases where the expected benefit to the mother exceeds the potential risk to the fetus.

In experimental studies it was found that pancreatin has no teratogenic effect.

Paediatric use

Paediatric use is possible according to the dosing regimen. The high lipase activity contained in pancreatin increases the likelihood of constipation in children.

Similarities